Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành hóa học dành cho các bạn yêu hóa học tham khảo đề tài: A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899 | DiPaola et al. Journal of Translational Medicine 2010 8 20 http www.translational-medicine.eom content 8 1 20 RESEARCH JOURNAL OF TRANSLATIONAL MEDICINE Open Access A randomized phase II trial of mitoxantrone estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer ECOG 3899 Robert S DiPaola1 Yu-Hui Chen2 Mark Stein1 David Vaughn3 Linda Patrick-Miller1 Michael Carducci4 Bruce Roth5 Eileen White6 George Wilding7 Abstract Background To test the hypothesis that modulation of Bcl-2 with 13-cis retinoic acid CRA interferon-alpha2b IFN with paclitaxel TAX or mitoxantrone estramustine and vinorelbine MEV will have clinical activity in men with metastatic castrate-resistant prostate cancer CRPC . Methods 70 patients were treated with either MEV Arm A in a 3-week cycle or CRA IFN TAX with an 8-week cycle Arm B . Patients were assessed for response toxicity quality of life QOL and the effect of treatment on Bcl-2 levels in peripheral blood mononuclear cells PBMC . Results The PSA response rates were 50 and 23 measurable disease response rates CR PR 14 and 15 and median overall survival 19.4 months and 13.9 months on Arm A and Arm B respectively. Transient grade 4 neutropenia occurred in 18 and 2 patients and grade 3 to 4 thrombosis in 7 patients and 1 patient in Arm A and Arm B respectively. Patients on Arm B reported a clinically significant decline in QOL between baseline and week 9 10 .71 s.d. and a significantly lower level of QOL than Arm A p 0.01 . As hypothesized Bcl-2 levels decreased with CRA IFN therapy only in Arm B p 0.03 . Conclusions Treatment with MEV was well tolerated and demonstrated clinical activity in patients with CRPC. Given the adverse effect of CRA IFN TAX on QOL the study of other novel agents that target Bcl-2 family proteins is warranted. The feasibility of measuring Bcl-2 protein in a cooperative group setting is hypothesis generating and .